ProMIS’s PMN310 Antibody Therapy Binds Only to Toxic Forms of Amyloid Beta, Study Reports

ProMIS’s PMN310 Antibody Therapy Binds Only to Toxic Forms of Amyloid Beta, Study Reports
An antibody therapy that ProMIS Neurosciences is developing for Alzheimer's formed a bond with only the harmful forms of amyloid beta clusters associated with the disease, an indication that it could be an effective treatment, according to a preclinical-trial study. A good sign was that PMN310 didn't bind to the forms that are non-toxic, ProMIS said. The study compared PMN310's binding characteristics with that of other amyloid beta-directed antibodies for Alzheimer’s. An antibody is a protein that the immune system produces when it detects harmful substances. An antibody therapy involves using an antibody to manage a condition. “We are pleased to confirm the selective binding of PMN310 to amyloid beta oligomers, a root cause of Alzheimer’s disease," Dr. Elliot Goldstein, ProMIS's president and chief executive officer, said in a press release. An oligomer is a molecular complex composed of up to five simpler molecules, or monomers. "Results of prior clinical studies with other amyloid beta antibody therapeutics clearly showed that antibodies targeting amyloid beta monomer have consistently been ineffective, while those targeting amyloid beta fibrils, the main component of plaque [build-up], are associated with a dose-limiting toxicity of brain swelling,” Goldstein said. “Taken together, results of prior clinical trials indicate the best-in-class target product profile i
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *